Quick Order

DLL4 / Delta-4 Antibody, Mouse MAb

    DatasheetReviewsRelated ProductsProtocols
    Human DLL4 Antibody Product Information
    Immunogen:Recombinant Human DLL4 protein (Catalog#10171-H08H)
    Clone ID:8H1D3G11
    Ig Type:Mouse IgG1
    Concentration:
    Endotoxin:
    Formulation:0.2 μm filtered solution in PBS with 5% trehalose
    Preparation:This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human DLL4 / Delta4 extracellular domain (rh DLL4; Catalog#10171-H08H; NP_061947.1; Met 1-Pro 524). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
    Human DLL4 Antibody Usage Guide
    Specificity:Human DLL4 / Delta-4
    Application:WB

    WB: 0.1-0.2 μg/mL

    Storage:
    Other DLL4 Antibody Products
    Reactivity: Human  
    Application: ELISA  
      10171-RP02-50
      10171-RP02-200
      10171-RP02-100
      50 µg 
      200 µg 
      100 µg 
      Add to Cart
      Reactivity: Human  
      Application: ELISA  
        10171-MM15-50
        10171-MM15-200
        10171-MM15-100
        50 µg 
        200 µg 
        100 µg 
        Add to Cart
        Reactivity: Human  
        Application: ELISA  
          10171-R003-50
          10171-R003-100
          10171-R003-1
          50 µg 
          100 µg 
          1 mg 
          Add to Cart
          Reactivity: Human  
          Application: ELISA  
            10171-RP01-400
            10171-RP01-200
            10171-RP01-100
            400 µg 
            200 µg 
            100 µg 
            Add to Cart
            Reactivity: Human  
            Application: ELISA  
              10171-MM06-50
              10171-MM06-200
              10171-MM06-100
              10171-MM06-1
              50 µg 
              200 µg 
              100 µg 
              1 mg 
              Add to Cart
              Reactivity: Mouse  
              Application: ELISA  
                50640-R006-50
                50640-R006-100
                50 µg 
                100 µg 
                Add to Cart
                Reactivity: Mouse  
                Application: ELISA  
                  50640-RP01-400
                  50640-RP01-200
                  50640-RP01-100
                  400 µg 
                  200 µg 
                  100 µg 
                  Add to Cart
                  Reactivity: Mouse  
                  Application: 
                    50640-R004-50
                    50640-R004-100
                    50640-R004-1
                    50 µg 
                    100 µg 
                    1 mg 
                    Add to Cart
                    Reactivity: Mouse  
                    Application: ELISA  
                      50640-RP02-50
                      50640-RP02-200
                      50640-RP02-100
                      50 µg 
                      200 µg 
                      100 µg 
                      Add to Cart
                      DLL4/Delta-like 4 Background

                      Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.

                      Human DLL4/Delta-like 4 References
                    • Yan M, et al. (2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 13(24): 7243-6.
                    • Sainson RC, et al. (2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med. 13(9): 389-95.
                    • Martinez JC, et al. (2009) Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54(5): 598-606.
                    • Li JL, et al. (2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7): 1099-103.
                    • Product nameProduct name
                      All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
                      Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"